DNA vaccination of mice against rabies virus: Effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL®)

Vaccine

Volumn 18, Issue 11-12, 2000, Pages 1059-1066

  Lodmell, Donald L ^a   Ray, Nancy B ^a   Ulrich, J Terry ^b   Ewalt, Larry C ^a  

^a Lab of Persistent Viral Diseases   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

DNA rabies vaccine; Monophosphoryl lipid A (MPL )

Indexed keywords

DNA VACCINE; IMMUNOLOGICAL ADJUVANT; MPL; PHOSPHORYL LIPID A; RABIES VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES; RABIES VIRUS; VACCINATION; VACCINE PRODUCTION; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; BIOLISTICS; INJECTIONS, INTRAMUSCULAR; LIPID A; MICE; MICE, INBRED BALB C; RABIES VACCINES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA;

EID: 0033990172     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00352-7     Document Type: Article

References (34)

1. Spencer L.M. Taking a bite out of rabies. J. Am. Vet. Med. Assoc. 204:1994;479-484.
2. Steele J.H. Rabies in the Americas and remarks on global aspects. Rev. Infect. Dis. 10:1988;585-597.
3. Meslin F.X., Fishbien D.B., Matter H.C. Rationale and prospects for rabies elimination in developing countries. Rupprecht C.E., Dietzschold B., Koprowski H. Lyssaviruses. 1994;1-26 Springer Verlag, New York.
4. Lai W.C., Bennett M. DNA vaccines. Crit. Rev. Immunol. 18:1998;449-484.
5. Xiang Z.Q., Spitalnik S., Tran M., Wunner W.H., Cheng J., Ertl H.C. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 199:1994;132-140.
6. Ray N.B., Ewalt L.C., Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine. 15:1997;892-895.
7. Lodmell D.L., Ray N.B., Ewalt L.C. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine. 16:1998;115-118.
8. Lodmell D.L., Ray N.B., Parnell M.J., Ewalt L.C., Hanlon C.A., Shaddock J.H., Sanderlin D.S., Rupprecht C.E. DNA immunization protects nonhuman primates against rabies virus. Nat. Med. 4:1998;949-952.
9. Xiang Z.Q., Spitalnik S.L., Cheng J., Erikson J., Wojczyk B., Ertl H.C. Immune responses to nucleic acid vaccines to rabies virus. Virology. 209:1995;569-579.
10. Johnson A.G., Gains S., Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody responses to protein antigens by purified lipopolysaccharide. J. Exp. Med. 103:1956;225-246.
11. Munoz J. Effects of bacteria and bacterial products on antibody response. Dixon F.J., Kunkel H.G. Advances in immunolgy. 1964;397-440 Academic Press, New York.
12. Johnson A.J. Adjuvant action of bacterial endotoxins on the primary antibody response. Landy M., Braun W. Bacterial endotoxins. 1964;252-262 University Press, New Brunswick.
13. Ribi E., Parker R., Strain S.M., Mizuno Y., Nowotony A., Von Eschen K.B., Cantrell J.L., McLaughlin C.A., Hwang K.M., Goren M.B. Peptides as requirement for immunotherapy of the guinea-pig Line 10 tumor with endotoxins. Cancer Immunol. Immunother. 7:1979;43-58.
14. Ribi E., Amano K., Cantrell J., Schwartzman S., Parker R., Takayama K. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol. Immunother. 12:1982;91-96.
15. Ribi E. Beneficial modification of the endotoxin molecule. J. Biol. Response Modifiers. 3:1984;1-9.
16. Takayama K., Ribi E., Cantrell J.L. Isolation of a nontoxic fraction containing tumor regression activity. Cancer Res. 41:1981;2654-2657.
17. Meyers K.R., Truchot A.T., Ward J., Hudson Y., Ulrich J.T. A critical determinant of lipid A endotoxic activity. Nowotony A., Spitzer J.J., Ziegler E.J. Cellular and molecular aspects of endotoxin reactions. 1990;145-156 Elsevier, Amsterdam.
18. Lodmell D.L. Genetic control of resistance to street rabies virus in mice. J. Exp. Med. 157:1983;451-460.
19. Smith J.S., Yager P.A., Baer G.M. A rapid reproducible test for determining rabies neutralizing antibody. Bull. Who. 48:1973;535-541.
20. Smith A.L., Tignor G.H., Mifune K., Motohashi T. Isoation and assay of rabies serogroup viruses in CER cells. Intervirology. 8:1977;92-99.
21. Gustafson G.L., Rhodes M.J. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143:1992;483-488.
22. Rickman L.S., Gordon D.M., Wistar R.J., Krzych U., Gross M., Hollingdale M.R., Egan J.E., Chulay J.D., Hoffman S.L. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 337:1991;998-1001.
23. Schneerson R., Fattom A., Szu S.C., Bryla D., Ulrich J.T., Rudbach J.A., Schiffman G., Robbins J.B. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol. 147:1991;2136-2140.
24. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. 1. Definition according to the profiles of lymphokine activities and secreted protein. J. Immunol. 138:1986;2348-2357.
25. Kuceroval L. DNA/genetic vaccination. Viral. Immunol. 11:1998;55-63.
26. + T cells in murine resistance to street rabies virus. J. Virol. 65:1991;3429-3434.
27. Sasaki S., Tsuji T., Hamajima K., Fukushima J., Ishii N., Kaneko T., Xin K-Q., Mohri H., Aoki I., Okubo T., Nishioka K., Okuda K. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Inf. Immun. 65:1997;3520-3528.
28. Battegay M., Moskophidis D., Waldner H., Bründler M.A., Fung-Leung W.-P., Mak T.W., Hengartner H., Zinkernagel R.M. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. J. Immunol. 151:1993;5408-5415. [published erratum appears in J. Immunol. 1994 Mar 1;152(5):1635].
29. Kawano H., Mifune K., Ohuchi M., Mannen K., Cho S., Hiramatsu K., Shichijo A. Protection against rabies in mice by a cytotoxic T cell clone recognizing the glycoprotein of rabies virus. J. Gen. Virol. 71:1990;281-287.
30. Fujii H., Mannen K., Takita-Sonoda Y., Hirai K., Cruz-Abrenica M.S.E., Kawano Y., Nishizono A., Mifune K. Target cells of cytotoxic T lymphocytes directed to the individual structural proteins of rabies virus. Microbiol. Immunol. 38:1994;721-726.
31. Ruegemer J.J., Ho S.N., Augustine J.A., Schlager J.W., Bell M.P., McKean D.J., Abraham R.T. Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J. Immunol. 144:1990;1767-1776.
32. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:1991;3815-3822.
33. Taga K., Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol. 148:1992;1143-1148.
34. Bachmann M.F., Kalinke U., Althage A., Freer G., Burkhart C., Roost H-P., Aguet M., Hengartner H., Zinkernagel R.M. The role of antibody concentration and avidity in antiviral protection. Science. 276:1997;2024-2027.